Found 10647 clinical trials
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified presence or absence of mutations in the
- 266 views
- 25 May, 2021
- 14 locations
Study in Parkinson Disease of Exercise
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax …
- 3 views
- 04 Jun, 2021
- 8 locations
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective:
- 23 views
- 09 Sep, 2021
- 4 locations
Sanofi COVID Booster Study
response induced by monovalent (D614)-AS03 vaccine. The secondary objectives of the study are: To assess the neutralizing and binding antibody profiles after primary series
- 894 views
- 16 Sep, 2021
- 2 locations
VAD00001: Respiratory Syncytial Virus (RSV) Study
Syncytial Virus (RSV) seronegative participants. The secondary objectives of the study are: To quantify the amount of vaccine virus shed by each participant by baseline
- 49 views
- 10 Sep, 2021
- 17 locations
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis
This is a Phase 1, multicenter, dose-escalation, open-label study to assess safety, tolerability, preliminary activity, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate-2 or high-risk myelofibrosis.
- 7 views
- 18 Jun, 2021
- 4 locations
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy. NCT02531516, PCR3003.
primary radiation therapy results in an improvement of metastasis-free survival. The study will include a Screening Phase, Treatment Phase, a Posttreatment Phase, and a Long-term Follow-up Phase.
- 57 views
- 02 Sep, 2021
- 1 location
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- 0 views
- 24 Jun, 2021
- 1 location
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- 0 views
- 24 Jun, 2021
- 1 location
AnaLysIs of Both Sex and Device Specific FactoRs on Outcomes in PAtients with Non-Ischemic Cardiomyopathy - Bio Libra
Secondary Objectives All-cause mortality, VT or VF alone, risk of cardiac death, and sudden cardiac death for the total cohort, as well as by sex and by the implanted
- 48 views
- 24 Nov, 2020
- 1 location